title: Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies.
abstract: Seven tumour markers, i.e. squamous cell carcinoma antigen (SCC), cancer antigen 125 (CA 125), tissue polypeptide antigen (TPA), neopterin, C-reactive protein (CRP), carcinoembryonic antigen (CEA) and deoxythymidine kinase (TK) were analysed in sera from 104 women with benign and 61 women with malignant gynecologic diseases, in order to create tumour marker panels for various gynecologic malignancies, for monitoring and prediction of disease development. The incidence of elevated tumour marker levels, in cervical carcinoma was 78% when SCC, CA 125 and CEA were used. In ovarian carcinoma one of the markers CA 125, TPA and CEA was elevated in 91% and for endometrial carcinoma the best combination of markers was SCC, CA 125 and CEA (57%). No individual marker was superior to the above combinations. However, in patients with a fatal outcome of their malignant gynecologic disease (mean survival time from serum sampling was 16 months), the incidence of death was highest among those who had TPA elevated (91%) followed by neopterin (86%) and CRP (76%). Although intercurrent diseases affected tumour marker levels the markers picked up a majority of patients with a poor prognosis. This demonstrates the importance of interpreting tumour marker results against a background of detailed clinical information.
authors.affiliation: Department of Obstetrics and Gynecology, Karolinska Hospital, Sweden.
authors.forename: E
authors.initials: E
authors.lastname: Avall Lundqvist
authors.forename: L
authors.initials: L
authors.lastname: Nordström
authors.forename: K
authors.initials: K
authors.lastname: Sjövall
authors.forename: P
authors.initials: P
authors.lastname: Eneroth
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000032:analysis; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis*; D001708:Biopterins / Q000031:analogs & derivatives / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000032:analysis; D005260:Female; D005831:Genital Diseases, Female / Q000276:immunology; D005833:Genital Neoplasms, Female / Q000175:diagnosis* / Q000276:immunology; D006801:Humans; D008875:Middle Aged; D019798:Neopterin; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000276:immunology; D010455:Peptides / Q000032:analysis; D015843:Serpins; D013937:Thymidine Kinase / Q000032:analysis; D019396:Tissue Polypeptide Antigen; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000276:immunology; D014594:Uterine Neoplasms / Q000175:diagnosis / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D010455:Peptides; D015843:Serpins; D019396:Tissue Polypeptide Antigen; C051072:squamous cell carcinoma-related antigen; D001708:Biopterins; D019798:Neopterin; D002097:C-Reactive Protein; D013937:Thymidine Kinase